David C Turner

7PUBLICATIONS
78CO-AUTHORS
PharmacogenomicsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 04, 2026
Pharmaceutical Industry Perspectives on Exposure-Response Confounding in Large Molecule Therapeutics: Results From an IQ Consortium Survey.

|Apr 01, 2026
Follow-Up Bias in Tumor Dynamic Modeling: A Comparison of Classical and Neural-ODE Approaches.

David C Turner, Mark Laurie, Shuhui Li

|Jun 27, 2025
Tocilizumab Dosing for Management of T Cell-Engaging Bispecific Antibody-Related CRS in Patients With R/R B-Cell NHL.

Candice Jamois, David C Turner, Leonid Gibiansky

|Apr 25, 2025
Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.

Junyi Li, Michael Z Liao, Justin Wilkins

|Nov 18, 2024
Clinical Pharmacology of Cytokine Release Syndrome with T-Cell-Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies.

Kendra K Radtke, Brendan C Bender, Zao Li

|May 29, 2024
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.

Brendan Bender, Chi-Chung Li, Mathilde Marchand

Pageof 2

Frequent Collaborators

3 joint publications

Chunze Li

3 joint publications

Chi-Chung Li

2 joint publications

Shweta Vadhavkar

2 joint publications

Jin Y Jin